Pharmaceutical Industry Capability Model

A detailed, multi-level capability map for the Pharmaceutical sector, covering 325+ business capabilities organized across three hierarchical levels. It's built around the R&D-to-regulatory-approval pipeline — discovery, clinical development, and FDA approval — a capability domain with no real equivalent in most other industries.

Why a capability model, not a prompt

A generic AI asked for "pharmaceutical capabilities" will typically default to a generic manufacturing-and-commercial list — make product, distribute product, sell product — because that's the shape of most industries it has seen. What that misses entirely is the capability domain that actually defines a pharmaceutical company and has no real equivalent elsewhere in business: a decade-plus pipeline from drug discovery through preclinical research through Phase I (safety and dosing), Phase II (efficacy), and Phase III (large-scale confirmatory) clinical trials, each phase gated by its own capabilities — trial design, patient recruitment, clinical data management — before a drug even reaches an FDA approval decision. It also misses that compliance here isn't one general obligation but three named, phase-specific standards — GLP for preclinical lab work, GCP for clinical trials, GMP for manufacturing — each with its own audit and inspection regime. And unlike a hospital, which delivers care, or a device manufacturer, which builds and iterates a physical product, a pharma company's commercial success depends on capabilities a generic list won't surface: patent and exclusivity lifecycle management that determines when generic competition arrives, and market access — payer negotiation, formulary placement, health-economics evidence — that determines whether an approved drug actually gets reimbursed and prescribed. This model treats R&D and clinical development as a first-class capability domain, with GxP compliance and market access built around it, instead of compressing the whole pipeline into a single "product development" line.

What's Inside

• Capability Map — 325+ capabilities across Level 1 (strategic), Level 2 (tactical), and Level 3 (operational), spanning R&D and clinical development, regulatory affairs, manufacturing, and commercial launch, in PowerPoint, Word, and Excel
• Capability Definitions — Clear, granular descriptions for consistent interpretation across R&D, regulatory, manufacturing, and commercial teams
• Capability KPIs — Level 2 measurable indicators to benchmark maturity and performance across the development-to-launch pipeline

How Teams Use It

• Scope a clinical trial management or clinical-data system against the specific Phase I–III trial capabilities it supports, instead of one generic "R&D systems" bucket
• Separate GLP (preclinical), GCP (clinical), and GMP (manufacturing) compliance capabilities when planning a quality or regulatory-systems initiative, since each has its own inspection regime
• Baseline patent and exclusivity lifecycle management and market-access capabilities ahead of a product launch or an approaching patent-cliff event
• Give R&D, regulatory affairs, manufacturing, and commercial teams a shared capability vocabulary across a pipeline that otherwise runs on phase-specific systems and language

Who It's For

Enterprise and business architects, R&D and clinical development leaders, regulatory affairs teams, and commercial/market-access leaders at biopharma and life sciences companies who need a capability structure built around the drug development pipeline, not a generic manufacturing model.